- Home
- EVI vs SCLXW Comparison
EVI vs SCLXW Comparison
Compare EVI & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVI
- SCLXW
- Stock Information
- Founded
- EVI 1959
- SCLXW N/A
- Country
- EVI United States
- SCLXW United States
- Employees
- EVI N/A
- SCLXW 117
- Industry
- EVI Other Consumer Services
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- EVI Consumer Discretionary
- SCLXW Health Care
- Exchange
- EVI Nasdaq
- SCLXW Nasdaq
- Market Cap
- EVI N/A
- SCLXW N/A
- IPO Year
- EVI N/A
- SCLXW N/A
- Fundamental
- Price
- EVI $17.36
- SCLXW $0.10
- Analyst Decision
- EVI
- SCLXW
- Analyst Count
- EVI 0
- SCLXW 0
- Target Price
- EVI N/A
- SCLXW N/A
- AVG Volume (30 Days)
- EVI 22.3K
- SCLXW 4.0K
- Earning Date
- EVI 05-08-2025
- SCLXW 03-07-2025
- Dividend Yield
- EVI 1.82%
- SCLXW N/A
- EPS Growth
- EVI 0.45
- SCLXW N/A
- EPS
- EVI 0.49
- SCLXW N/A
- Revenue
- EVI $360,461,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- EVI N/A
- SCLXW N/A
- Revenue Next Year
- EVI N/A
- SCLXW N/A
- P/E Ratio
- EVI $34.26
- SCLXW N/A
- Revenue Growth
- EVI N/A
- SCLXW 22.02
- 52 Week Low
- EVI $14.51
- SCLXW $0.18
- 52 Week High
- EVI $25.00
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- EVI 46.71
- SCLXW N/A
- Support Level
- EVI $16.59
- SCLXW N/A
- Resistance Level
- EVI $18.82
- SCLXW N/A
- Average True Range (ATR)
- EVI 1.10
- SCLXW 0.00
- MACD
- EVI -0.18
- SCLXW 0.00
- Stochastic Oscillator
- EVI 17.66
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.